---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-045054"
form_type: "8-K"
ticker: "CPIX"
cik: "0001087294"
company_name: "CUMBERLAND PHARMACEUTICALS INC"
filed_at: "2024-11-04T23:59:59+00:00"
generated_at: "2026-05-30T05:47:23.192650+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# CMS denies Caldolor separate Medicare reimbursement under NOPAIN Act for CY2025

## Summary
- CMS excluded Caldolor from NOPAIN Act separate payment list announced Nov 1, 2024 for CY2025.
- CMS concluded Caldolor does not qualify because FDA indication lacks mention of post-operative use.
- Company submitted comments in July 2023 and July 2024 arguing Caldolor meets statutory requirements.
- Company says majority of Caldolor use is surgical and FDA approval based on post-surgical pain studies.
- Cumberland is evaluating options; calls CMS determination inconsistent with NOPAIN Act intent.

## SEC filing metadata
- accession: 0001628280-24-045054
- form_type: 8-K
- ticker: CPIX
- cik: 0001087294
- company_name: CUMBERLAND PHARMACEUTICALS INC
- filed_at: 2024-11-04T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1087294/000162828024045054/0001628280-24-045054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1087294/000162828024045054/cpix-20241104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-045054
- JSON: https://secwatch.observer/filing/0001628280-24-045054.json
- Plain text: https://secwatch.observer/filing/0001628280-24-045054.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.